A call to action for the new decade of vaccines

The Lancet

Volumn 378, Issue 9788, 2011, Pages 298-302

  Moxon, E Richard ^a   Das, Pamela ^b   Greenwood, Brian ^c   Heymann, David L ^c   Horton, Richard ^b   Levine, Orin S ^d   Plotkin, Stanley ^e   Nossal, Gus ^f  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b THE LANCET   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GLYCOCONJUGATE VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MEASLES VACCINE; MENAFRIVAC; MENINGOCOCCUS A VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHILD DEATH; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; DIARRHEA; DISEASE SEVERITY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG LEGISLATION; DRUG SAFETY; DRUG STABILITY; ECONOMIC DEVELOPMENT; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; FUNDING; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFECTION; INFECTION PREVENTION; LICENSING; MALARIA; MEASLES; MENINGITIS; MORTALITY; NOTE; PNEUMONIA; PRIORITY JOURNAL; PUBLIC HEALTH; RESPIRATORY TRACT DISEASE; STREPTOCOCCUS PNEUMONIA; TUBERCULOSIS; VACCINE PRODUCTION; WORLD HEALTH ORGANIZATION;

EID: 79960745747     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60766-6     Document Type: Note

References (21)

1. SA Plotkin Vaccines, the fourth century Clin Vacc Immunol 16 2009 1709 1719
2. DE Bloom, D Canning, M Weston The value of vaccination World Economics 6 2010 15 19
3. T Bärnighausen, DE Bloom, D Canning et al. Rethinking the benefits and costs of childhood vaccination: the example of the Haemophilus influenzae type b vaccine Vaccine 29 2011 2371 2380
4. Nossal GJV. Vaccines and future global health needs. Phil Trans R Soc B (in press).
5. A Chandran, S Fitzwater, A Zhen, M Santosham Prevention of rotavirus gastroenteritis in infants and children: rotavirus vaccine safety, efficacy, and potential impact of vaccines Biologics 4 2010 213 229
6. KL O'Brien, LJ Wolfson, JP Watt for the Hib and Pneumococcal Global Burden of Disease Study Team Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates Lancet 374 2009 893 902
7. S Low, M Kraemer, M Schneider, AM Restrepo Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis Vaccine 26 2008 383 398
8. GAVI Alliance Facts and figures http://www.gavialliance.org/media-centre/ facts/index/php (accessed May 18, 2011).
9. FM LaForce, N Ravenscroft, M Djingarey, S Vivivani Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution Vaccine 27 suppl 2 2009 B13 B19
10. JR Hargreaves, B Greenwood, C Clift et al. Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines Lancet 2011 10.1016/S0140-6736(11)60687-9 published online June 9.
11. R Rappuoli, S Black, PH Lambert Vaccine discovery and translation of new vaccine technology Lancet 2011 10.1016/S0140-6736(11)60440-6 published online June 9.
12. J Smith, M Lipsitch, JW Almond Vaccine production, distribution, access, and uptake Lancet 2011 10.1016/S0140-6736(11)60478-9 published online June 9.
13. ER Moxon, C-A Siegrist The next decade of vaccines: societal and scientific challenges Lancet 2011 10.1016/S0140-6736(11)60407-8 published online June 9.
14. HJ Larson, LZ Cooper, J Eskola, SL Katz, S Ratzan Addressing the vaccine confidence gap Lancet 2011 10.1016/S0140-6736(11)60678-8 published online June 9.
15. G Kersten, H Hirschberg Needle-free vaccine delivery Expert Opin Drug Deliv 4 2007 459 474 (Pubitemid 47527329)
16. J Clemens, L Jodar Introducing new vaccines into developing countries, obstacles, opportunities and complexities Nature Med 11 2005 S12 S15
17. NS Padian, A Buve, J Balkus, D Serwaada, W Cates Jr. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward Lancet 372 2008 585 599
18. TJ Coates, L Richter, C Caceres Behavioural strategies to reduce HIV transmission: how to make them work better Lancet 372 2008 669 684
19. J Shiffman Issue attention in global health: the case of newborn survival Lancet 375 2010 2045 2049
20. GAVI Alliance The GAVI Alliance strategy and business plan 2011-2015 http://www.gavialliance.org/resources/Doc-4-GAVI-Strategy-and-Business-Plan.pdf (accessed May 18, 2011).
21. K Senouci, J Blau, B Nyambat et al. The Supporting Independent Immunization and Vaccine Advisory Committees (SIVAC) initiative: a country-driven, multi-partner program to support evidence-based decision making Vaccine 28 suppl 1 2010 A26 A30